Associations Between Lipid-Derived Indices and Cardiovascular–Kidney–Metabolic Syndrome Progression Among Chinese Middle-Aged and Elderly Adults: A Longitudinal Study

Why It Matters

These lipid‑derived markers offer clinicians inexpensive tools to flag individuals at heightened risk of CKM progression, enabling earlier preventive measures. The superior performance of NHHR positions it as a practical addition to routine risk assessment protocols.

Key Takeaways

• Seven lipid indices predict CKM progression
• NHHR shows strongest CVD predictive power
• Remnant cholesterol not linked to CKM risk
• Linear and nonlinear risk patterns observed
• Study uses nationwide Chinese cohort data

Pulse Analysis

Cardiovascular‑kidney‑metabolic syndrome sits at the nexus of three major chronic disease pathways, and its rising prevalence among aging populations poses a growing public‑health challenge. Traditional risk models often rely on invasive testing or costly imaging, leaving a gap for simple, blood‑based indicators. Lipid metabolism, intimately tied to atherosclerosis, insulin resistance, and renal dysfunction, provides a fertile ground for such markers, prompting researchers to explore composite indices that capture nuanced metabolic disturbances.

The CHARLS longitudinal analysis leveraged a decade of data to evaluate eight lipid‑derived indices, revealing that seven of them consistently correlated with higher cardiovascular event risk across CKM stages. Notably, the non‑HDL‑C to HDL‑C ratio (NHHR) emerged as the top performer, delivering a C‑index of 0.632—an appreciable gain over conventional single‑parameter models. Restricted cubic spline modeling added depth, showing that while AIP, NHHR, LCI and TyG followed linear risk trajectories, LAP and VAI exhibited threshold effects, suggesting that extreme visceral fat accumulation may accelerate disease progression.

For clinicians and health systems, these findings translate into actionable intelligence. Incorporating NHHR and related indices into electronic health records could flag high‑risk patients during routine lipid panels, prompting lifestyle counseling, tighter glycemic control, or early referral to nephrology and cardiology services. Moreover, the study’s methodology—using a large, representative Chinese cohort—offers a template for similar investigations in other demographics, including the United States, where CKM‑related morbidity drives substantial costs. Future research should validate these markers across ethnic groups and explore integration with emerging biomarkers to refine precision‑medicine approaches for chronic disease prevention.